BioNxt Solutions Shares Gain on Promising Preclinical Trial Results

Investor attention has returned to BioNxt Solutions following the release of encouraging new laboratory data. The company’s latest preclinical study results for its multiple sclerosis (MS) drug delivery platform have provided a boost to the stock. The central question for the market is whether this news can provide a lasting foundation for a share price recovery.

On January 21, BioNxt announced final preclinical results that are driving the current positive sentiment. The study, conducted using a swine model, demonstrated that the company’s proprietary sublingual orally dissolving film (ODF) formulation of the drug Cladribine achieved significantly greater drug absorption than conventional oral tablets.

Key findings from the Read more...